MERUS N V's ticker is MRUS and the CUSIP is N5749R100. A total of 100 filers reported holding MERUS N V in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,141,970 | -50.3% | 430,109 | -44.5% | 9.19% | -18.7% |
| Q2 2023 | $20,408,620 | -9.5% | 775,109 | -36.7% | 11.31% | +21.1% |
| Q1 2023 | $22,542,006 | +1.7% | 1,225,109 | -14.5% | 9.34% | +12.3% |
| Q4 2022 | $22,154,726 | -26.6% | 1,432,109 | -5.0% | 8.32% | -23.5% |
| Q3 2022 | $30,187,000 | -9.7% | 1,507,109 | +2.0% | 10.88% | -4.7% |
| Q2 2022 | $33,442,000 | +0.3% | 1,477,109 | +17.1% | 11.41% | +132.8% |
| Q1 2022 | $33,355,000 | +17.0% | 1,261,534 | +40.7% | 4.90% | +51.6% |
| Q4 2021 | $28,509,000 | +205.9% | 896,502 | +16.4% | 3.23% | -11.0% |
| Q1 2020 | $9,319,000 | -36.3% | 770,183 | -25.9% | 3.63% | -33.9% |
| Q4 2019 | $14,626,000 | -21.0% | 1,038,746 | 0.0% | 5.49% | -57.9% |
| Q3 2019 | $18,510,000 | -9.2% | 1,038,746 | -25.4% | 13.04% | +84.2% |
| Q2 2019 | $20,385,000 | -7.5% | 1,391,497 | -6.7% | 7.08% | -27.4% |
| Q1 2019 | $22,029,000 | +6.3% | 1,491,497 | +0.7% | 9.75% | -2.8% |
| Q4 2018 | $20,732,000 | – | 1,480,855 | – | 10.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,600,000 | $32,048,000 | 13.34% |
| Lynx1 Capital Management LP | 613,071 | $12,280,000 | 11.08% |
| Aquilo Capital Management, LLC | 1,507,109 | $30,187,000 | 10.88% |
| COMMODORE CAPITAL LP | 2,615,762 | $52,394,000 | 8.42% |
| MPM BioImpact LLC | 918,310 | $18,394,000 | 4.36% |
| BVF INC/IL | 3,444,420 | $68,992,000 | 2.85% |
| Boxer Capital, LLC | 1,900,000 | $38,057,000 | 2.14% |
| Opaleye Management Inc. | 253,200 | $5,072,000 | 2.10% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 295,136 | $5,912,000 | 2.00% |
| TCG Crossover Management, LLC | 300,000 | $6,009,000 | 1.80% |